Biomarker-Defined Metastatic Solid Tumors

Too many loved ones live with uncertainty.
Let’s find answers.

Precision medicine is transforming how we treat cancer. We know that a patient’s response to treatment can depend on the genetic makeup of their cancer and are applying a precision medicine approach to develop new treatments for a number of highly prevalent, biomarker-defined metastatic cancers. Our ambition is for patients with cancer to lead longer, better lives.

Let’s go vertical

We are collaborating with BeiGene to take a vertical inhibition approach to the MAPK pathway. A study combining our MEK inhibitor with BeiGene’s RAF dimer inhibitor represents a unique opportunity to treat patients with MAPK-driven cancers, particularly those with RAS mutations, where rational targeted therapies are urgently needed for patients. We believe that through a potent and optimized vertical inhibition combination therapy approach, we may be able to address several biomarker-defined patient subsets within the broader MAPK-mutated solid tumor space.

RAF mutant solid tumors
A Phase 1b trial is evaluating brimarafenib (BGB-3245) in adult patients with RAF mutant solid tumors in the second half of 2024. Brimarafenib is an investigational, selective RAF dimer inhibitor being developed by MapKure, LLC, a joint venture between SpringWorks and BeiGene, Ltd.
MAPK mutant solid tumors
A Phase 1b study is evaluating brimarafenib in combination with mirdametinib, our investigational MEK inhibitor, in patients with MAPK mutant solid tumors.
Colorectal and pancreatic cancer
A Phase 1b trial is evaluating brimarafenib in combination with panitumumab, a monoclonal antibody targeting Epidermal Growth Factor Receptor in colorectal and pancreatic cancer patients with known MAPK pathway mutations.
RAS/RAF mutant
solid tumors
A Phase 1b/2 clinical trial is evaluating mirdametinib in combination with lifirafenib, BeiGene’s investigational RAF dimer inhibitor in patients with advanced or refractory solid tumors that harbor RAS mutations, RAF mutations and other MAPK pathway.